Compare SUNS & NORD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | NORD |
|---|---|---|
| Founded | 2023 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Professional Services |
| Sector | Real Estate | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7M | 95.5M |
| IPO Year | 2024 | 2005 |
| Metric | SUNS | NORD |
|---|---|---|
| Price | $6.96 | $3.72 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.25 | N/A |
| AVG Volume (30 Days) | ★ 79.8K | 35.4K |
| Earning Date | 11-10-2026 | 07-25-2017 |
| Dividend Yield | ★ 17.86% | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $21,571,434.00 | $3,346.00 |
| Revenue This Year | $91.54 | N/A |
| Revenue Next Year | $12.74 | N/A |
| P/E Ratio | $12.43 | ★ N/A |
| Revenue Growth | ★ 102.96 | N/A |
| 52 Week Low | $5.77 | $3.38 |
| 52 Week High | $10.45 | $5.28 |
| Indicator | SUNS | NORD |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | N/A |
| Support Level | $6.20 | N/A |
| Resistance Level | $7.90 | N/A |
| Average True Range (ATR) | 0.27 | 0.00 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 80.00 | 0.00 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.
Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.